51044 Federal Register / Vol. 76, No. 159 / Wednesday, August 17, 2011 / Notices 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Arthritis and 

Musculoskeletal and Skin Diseases; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Arthritis and Musculoskeletal 

and Skin Diseases Advisory Council. 

The meeting will be open to the 

public as indicated below, with 

attendance limited to space available. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Arthritis and 

Musculoskeletal and Skin Diseases Advisory 

Council. 

Date: September 27, 2011. 

Open: 8:30 a.m. to 12 p.m. 

Agenda: To discuss administrative details 

relating to the Council’s business and special 

reports. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 6, Bethesda, MD 20892. 

Closed: 1 p.m. to 5 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Building 31, 31 Center Drive, Conference 

Room 6, Bethesda, MD 20892. 

Contact Person: Laura K Moen, PhD, 

Director, Division of Extramural Research 

Activities, NIAMS/NIH, 6701 Democracy 

Blvd., Ste 800, Bethesda, MD 20892, 301– 

451–6515, moenl@mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

In the interest of security, NIH has 

instituted stringent procedures for entrance 

onto the NIH campus. All visitor vehicles, 

including taxicabs, hotel, and airport shuttles 

will be inspected before being allowed on 

campus. Visitors will be asked to show one 

form of identification (for example, a 

government-issued photo ID, driver’s license, 

or passport) and to state the purpose of their 

visit. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.846, Arthritis, 

Musculoskeletal and Skin Diseases Research, 

National Institutes of Health, HHS) 

Dated: August 11, 2011. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–20946 Filed 8–16–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(a) of the 

Federal Advisory Committee Act, as 

amended (5 U.S.C. App.), notice is 

hereby given of a meeting of the 

National Cancer Institute Director’s 

Consumer Liaison Group. 

The meeting will be open to the 

public, with attendance limited to space 

available. Individuals who plan to 

attend and need special assistance, such 

as sign language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

Name of Committee: National Cancer 

Institute Director’s Consumer Liaison Group 

DCLG. 

Date: September 21–23, 2011. 

Time: 12 p.m. to 12 p.m. 

Agenda: 09/21 Welcome and review of 

how science is changing; 09/22 The role of 

regulatory science; 09/23 How is NIH/NCI 

responding to the changes in the Clinical 

Trials Process? What can the advocacy 

community do to create a broader 

understanding about this imperative for 

change and support these changes moving 

forward? 

Place: Embassy Suites Hotel at Chevy 

Chase, 4300 Military Road, NW., Washington 

DC, 20015. 

Contact Person: Shannon K. Bell, MSW, 

Director, Office of Advocacy Relations, 

National Cancer Institute, National Institutes 

of Health, 31 Center Drive, Building 31, 

Room 10A30D, Bethesda, MD 20892. 301– 

451–3393. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: 

deainfo.nci.nih.gov/advisory/dclg/dclg.htm, 

where an agenda and any additional 

information for the meeting will be posted 

when available. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 11, 2011. 

Anna P. Snouffer, 

Deputy Director, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2011–20944 Filed 8–16–11; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–1243. 

Project: SAMHSA SOAR Web-Based 

Data Form—NEW 

In 2009 the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) of the U.S. Department of 

Health and Human Services created a 

Technical Assistance Center to assist in 

the implementation of the SSI/SSDI 

Outreach Access and Recovery (SOAR) 

effort in all states. SOAR’s primary 

objective is to improve the allowance 

rate for Social Security Administration 

(SSA) disability benefits for people who 

are homeless or at risk of homelessness, 

and who have serious mental illnesses. 

SOAR has three main components: 

strategic planning for systems change, 

training for case managers and ongoing 

technical assistance. 

During the SOAR training, the 

importance of keeping track of SSI/SSDI 

applications through the process is 

stressed, since the process is complex 

and involves several steps. In response 

to requests from states implementing 

SOAR, the Technical Assistance Center 

under SAMHSA’s direction developed a 

web-based data form that case managers 

can use to track the progress of 

submitted applications, including 


Emcdonald on DSK2BSOYB1PROD with NOTICES
Federal Register / Vol. 76, No. 159 / Wednesday, August 17, 2011 / Notices 51045 

decisions received from SSA either on 

initial application or on appeal. This 

password-protected web-based data 

form will be housed on the SOAR Web 

site (http://www.prainc.com/soar). Use 

of this form is completely voluntary. 

In addition, data from the web-based 

form can be compiled into reports on 

decision results and the use of SOAR 

core components, such as the SSA–1696 

Appointment of Representative which 

allows SSA to communicate directly 

with the case manager assisting with the 

application. These reports will be 

reviewed by agency directors, SOAR 

state-level leads, and the national SOAR 

Technical Assistance Center and SOAR 

national evaluation team to quantify the 

success of the effort overall and to 

identify areas where additional 

technical assistance is needed. 

The estimated response burden is as 

follows: 

Information source Number of 

respondents 

Responses 

per 

respondent 

Total 

responses 

Hours per 

response 

Total 

hours 

SOAR Data Form ............................................. 800 36 28,800 .25 7,200 

Written comments and 

recommendations concerning the 

proposed information collection should 

be sent by September 16, 2011 to the 

SAMHSA Desk Officer at the Office of 

Information and Regulatory Affairs, 

Office of Management and Budget 

(OMB). To ensure timely receipt of 

comments, and to avoid potential delays 

in OMB’s receipt and processing of mail 

sent through the U.S. Postal Service, 

commenters are encouraged to submit 

their comments to OMB via e-mail to: 

OIRA_Submission@omb.eop.gov. 

Although commenters are encouraged to 

send their comments via e-mail, 

commenters may also fax their 

comments to: 202–395–7285. 

Commenters may also mail them to: 

Office of Management and Budget, 

Office of Information and Regulatory 

Affairs, New Executive Office Building, 

Room 10102, Washington, DC 20503. 

Cathy J. Friedman, 

SAMHSA, Public Health Analyst. 

[FR Doc. 2011–20856 Filed 8–16–11; 8:45 am] 

BILLING CODE 4162–20–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Agency Information Collection 

Activities: Submission for OMB 

Review; Comment Request 

Periodically, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA) will publish a summary of 

information collection requests under 

OMB review, in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 

documents, call the SAMHSA Reports 

Clearance Officer on (240) 276–1243. 

Project: Children Affected by 

Methamphetamine in Family Drug 

Treatment Court—NEW 

In 2010, the Substance Abuse and 

Mental Health Services Administration 

(SAMHSA), Center for Substance Abuse 

Treatment (CSAT), provided funding to 

12 existing Family Treatment Drug 

Courts (FTDCs) for enhancement and/or 

expansion of their FTDC’s capabilities 

to provide psycho-social, emotional and 

mental health services to children (0–17 

years) and their families who have 

methamphetamine use disorders and 

involvement in child protective 

services. This program was authorized 

in House Report 111–220 accompanying 

H.R. 3293 in 2010. The Committee 

language stated that ‘‘these grants will 

support a collaborative approach, 

including treatment providers, child 

welfare specialists, and judges, to 

provide community-based social 

services for the children of 

methamphetamine-addicted parents,’’ 

and were to be awarded to Family 

Dependency Treatment Drug Courts. 

The proposed data collection for the 

grantees, referred to as the Children 

Affected by Methamphetamine in 

Family Treatment Drug Court (CAM– 

FTDC) project, will provide knowledge 

about the services needed and provided 

to these and similar families. The data 

to be collected by the CAM–FTDC 

program is SAMHSA’s first Federal data 

collection effort focused specifically on 

the needs of children whose parents 

have a substance use disorder and are 

participating in an FTDC and on 

effective strategies to address their 

needs. The information collected 

through the CAM–FTDC program will 

benefit SAMHSA by providing an indepth understanding of the needs of the 

children and families served by CAM– 

FTDC. Findings from this program will 

provide SAMHSA with valuable 

information regarding appropriate 

service interventions for this population 

and, ultimately, inform SAMHSA on 

how the agency can best meet the needs 

of future drug endangered children. The 

results from this data collection will 

serve to inform future decisions 

regarding funding by SAMHSA as well 

as establish an evidence base for the 

practices undertaken for other localities 

and programs implementing Family 

Treatment Drug Courts. 

The evaluation of the CAM–FTDC 

project will collect data on children, 

parents/caregivers, family functioning 

and interagency collaboration. The 

domains specified in the Request for 

Applications (RFA) are: (1) Child 

Outcomes; (2) Parent/Caregiver 

Outcomes; (3) Family Functioning; and, 

(4) Interagency Collaboration. 

To the greatest extent possible, the 

data elements are operationally defined 

using standard definitions in child 

welfare and substance abuse treatment. 

The use of standard data definitions 

will reduce the data collection burden 

on grantees as these variables are 

collected through data collection 

procedures that currently exist through 

all publically funded child welfare and 

substance abuse treatment systems. The 

CAM–FTDC performance measures are 

data currently collected by programs as 

part of their normal operations (e.g., 

placement status in child welfare 

services, substance abuse treatment 

entry dates). Thus, no primary data 

collection from clients will be required 

as the grantees will be abstracting 

existing data. The information utilized 

for the North Carolina Family 

Assessment Scale rating is obtained 

during the intake interview that sites 

engage in when determining program 

eligibility and suitability. If needed, the 

CAM FTDC staff member may 

supplement this information by 

obtaining information from other staff 

that interact with the client (i.e., the 

social worker familiar with the family) 

or during a home visit (if this is part of 

their program activities). 

It should be re-emphasized that the 

CAM–FTDC projects are expansions or 

enhancements of FTDC partnerships 

that currently have existing 

relationships (and information sharing/ 


Emcdonald on DSK2BSOYB1PROD with NOTICES